Stonepine Capital Management LLC Buys 40,000 Shares of Aquestive Therapeutics, Inc. $AQST

Stonepine Capital Management LLC lifted its stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 25.0% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 200,000 shares of the company’s stock after acquiring an additional 40,000 shares during the period. Stonepine Capital Management LLC owned 0.20% of Aquestive Therapeutics worth $580,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in AQST. Pale Fire Capital SE increased its position in Aquestive Therapeutics by 154.1% in the 1st quarter. Pale Fire Capital SE now owns 1,335,684 shares of the company’s stock worth $3,873,000 after buying an additional 809,928 shares during the period. Janney Montgomery Scott LLC increased its position in Aquestive Therapeutics by 7.6% in the 1st quarter. Janney Montgomery Scott LLC now owns 1,059,760 shares of the company’s stock worth $3,073,000 after buying an additional 75,275 shares during the period. Bank of America Corp DE increased its position in Aquestive Therapeutics by 905.2% in the 4th quarter. Bank of America Corp DE now owns 690,284 shares of the company’s stock worth $2,457,000 after buying an additional 621,614 shares during the period. Northern Trust Corp increased its position in Aquestive Therapeutics by 3.1% in the 4th quarter. Northern Trust Corp now owns 599,812 shares of the company’s stock worth $2,135,000 after buying an additional 18,199 shares during the period. Finally, Harvey Capital Management Inc. increased its position in Aquestive Therapeutics by 86.8% in the 1st quarter. Harvey Capital Management Inc. now owns 499,570 shares of the company’s stock worth $1,449,000 after buying an additional 232,180 shares during the period. 32.45% of the stock is owned by institutional investors.

Aquestive Therapeutics Price Performance

Shares of Aquestive Therapeutics stock opened at $3.98 on Friday. The firm has a market capitalization of $396.89 million, a PE ratio of -5.69 and a beta of 1.99. The company’s fifty day moving average price is $3.82 and its two-hundred day moving average price is $3.18. Aquestive Therapeutics, Inc. has a 52-week low of $2.12 and a 52-week high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. The business had revenue of $10.00 million for the quarter, compared to the consensus estimate of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. Analysts predict that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

AQST has been the topic of several recent analyst reports. Zacks Research raised Aquestive Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 13th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research report on Tuesday, June 17th. Finally, Oppenheimer initiated coverage on Aquestive Therapeutics in a research report on Monday, June 2nd. They issued an “outperform” rating and a $7.00 price target on the stock. Seven investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, Aquestive Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $10.14.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.